Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Argus Health
McKesson
Medtronic
Teva
Moodys

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 9,688,760

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,688,760
Title:Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
Abstract: The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20.times.CD3 or a CD19.times.CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment. Such anti-adhesive type compounds include, but are not limited to, antibodies, like natalizumab, efalizumab, and etrolizumab; minocycline, (acetyl-)salicyclic acid, astilbin, and flavonoids; and thrombin and pentosanpolysulfate (PPS), or a pharmaceutically acceptable salt thereof.
Inventor(s): Kufer; Peter (Munich, DE), Nagorsen; Dirk (Munich, DE), Scheele; Juergen (Munich, DE), Zugmaier; Gerhard (Munich, DE), Klinger; Matthias (Gilching, DE), Hoffmann; Patrick (Bad Heilbrunn, DE), Naegele; Virginie (Munich, DE), Dopfer; Elaine-Pashupati (Munich, DE)
Assignee: AMGEN RESEARCH (MUNICH) GMBH (Munich, DE)
Application Number:14/176,091
Patent Claims:see list of patent claims

Details for Patent 9,688,760

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up AMGEN RESEARCH (MUNICH) GMBH (Munich, DE) 2033-02-08 RX search
Amgen BLINCYTO blinatumomab INJECTABLE;INJECTION 125557 001 2014-12-03 ➤ Sign Up AMGEN RESEARCH (MUNICH) GMBH (Munich, DE) 2033-02-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Argus Health
Citi
Federal Trade Commission
Healthtrust
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.